All canine diagnoses

Your dog was diagnosed with Hepatocellular Carcinoma. Most common primary hepatic tumour in dogs. Three morphological forms: massive (single large mass — ~55%, best prognosis), nodular (multiple nodules — ~30%), diffuse (~15%, worst prognosis). Many are incidental findings on abdominal imaging. Compare 3 treatment options for dogs including Liver Lobectomy (Massive Form), Systemic Chemotherapy (Unresectable), Supportive Care / Palliation — with survival times, costs, and what to expect during treatment.

🐕

Hepatocellular Carcinoma

BreedsNo strong breed predispositionPossibly Miniature SchnauzerMale predisposition reported
canine

Epithelial

About This Cancer

Hepatocellular carcinoma is the most common primary liver cancer in dogs, arising from hepatocytes — the main functional cells of the liver. It occurs in three distinct forms: massive (a single large tumour in one liver lobe, about 55% of cases), nodular (multiple tumour nodules across the liver, about 30%), and diffuse (cancer spread throughout the liver, about 15%). This distinction is critically important because the massive form can often be cured by surgically removing the affected liver lobe, whereas the nodular and diffuse forms are generally not amenable to complete surgical removal. Many hepatocellular carcinomas are discovered incidentally during imaging for other reasons, as they can grow to a substantial size before causing clinical signs. When symptoms do develop, they may include lethargy, reduced appetite, weight loss, or abdominal distension. The liver has remarkable regenerative capacity, and dogs typically recover well from surgical removal of even a large portion.

Morphological classification

Canine HCC classified by morphological pattern rather than formal TNM staging

Stage MassiveSingle large mass involving one liver lobe — best prognosis, most surgically amenable
Stage NodularMultiple discrete nodules across liver lobes — intermediate prognosis
Stage DiffuseInfiltrative involvement of multiple/all lobes — worst prognosis, not surgically amenable
Prognostic Factors(3)
Morphological typeMassive: MST >1,460 days post-lobectomy. Nodular/diffuse: MST 270-428 days. Single strongest prognostic factor.(Matsuyama et al., 2004)
Completeness of excisionComplete excision of massive HCC is often curative. Incomplete excision carries much worse prognosis.(Matsuyama et al., 2004)
Tumour rupture/haemoperitoneumRuptured HCC presenting as emergency has worse prognosis but surgery can still be beneficial.
Minimum Workup(7 steps)
1Abdominal ultrasound (characterise mass type — massive vs nodular vs diffuse)
2Abdominal CT (surgical planning, assess resectability)
3Complete blood count and serum biochemistry (liver values, albumin)
4Coagulation panel (PT, PTT, fibrinogen — hepatic coagulopathy risk)
5Thoracic radiographs (3-view) for pulmonary metastasis
6FNA of mass (cytology can suggest HCC but may not distinguish from adenoma)
7Consider Tru-Cut biopsy if FNA inconclusive

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
Liver Lobectomy (Massive Form)
~48 mo
Systemic Chemotherapy (Unresectable)
~12 mo (6–18)
Supportive Care / Palliation
~9 mo (3–14)
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.